Humana Extends Slide as Piper Sandler Downgrades on Star Ratings Update
Humana Cut to Neutral From Overweight by Piper Sandler
Bernstein Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $405
Piper Sandler Downgrades Humana(HUM.US) to Hold Rating, Cuts Target Price to $274
Deutsche Bank Maintains Humana(HUM.US) With Hold Rating, Announces Target Price $250
Humana (HUM) Receives a Hold From Deutsche Bank
A Quick Look at Today's Ratings for Humana(HUM.US), With a Forecast Between $247 to $402
Humana Is Maintained at Outperform by Oppenheimer
Truist Financial Releases a Hold Rating on Humana (HUM)
Oppenheimer Adjusts Price Target on Humana to $280 From $400, Maintains Outperform Rating
B of A Securities Downgrades Humana to Underperform, Lowers Price Target to $247
Humana's Star Rating Decline Prompts Hold Rating Amid Financial Uncertainty
Buy Rating Affirmed: Humana's Proactive Strategies to Mitigate Earnings Headwinds
Humana Analyst Ratings
Humana Price Target Cut to $250.00/Share From $400.00 by Leerink Partners
Humana Cut to Market Perform From Outperform by Leerink Partners
J.P. Morgan Weighs in on Humana Stock Following Medicare Star Rating Changes
Stephens Downgrades Humana to Equalweight From Overweight, Cuts Price Target to $250 From $400
Wolfe Research Maintains Humana(HUM.US) With Buy Rating, Cuts Target Price to $342
Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $395 Price Target